Analysts Offer Insights on Healthcare Companies: Pieris Pharmaceuticals (PIRS) and SCYNEXIS (SCYX)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pieris Pharmaceuticals (PIRS) and SCYNEXIS (SCYX) with bullish sentiments.

Pieris Pharmaceuticals (PIRS)

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Pieris Pharmaceuticals, with a price target of $5. The company’s shares closed yesterday at $3.34.

Pantginis wrote:

“Valuation and risks to price target achievement. We maintain our Buy rating and $5 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Pieris Pharmaceuticals, Inc.”

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -14.2% and a 29.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Iovance Biotherapeutics Inc.

Pieris Pharmaceuticals has an analyst consensus of Moderate Buy.

See today’s analyst top recommended stocks >>

SCYNEXIS (SCYX)

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on SCYNEXIS today and set a price target of $4.50. The company’s shares closed yesterday at $1.62.

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 12.3% and a 55.6% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Zynerba Pharmaceuticals.

Currently, the analyst consensus on SCYNEXIS is a Strong Buy with an average price target of $6.33, representing a 290.7% upside. In a report issued on March 15, Needham also maintained a Buy rating on the stock with a $5 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts